Since its establishment, Rendu Biotech has maintained an innovation-driven core, with research and development (R&D) innovation fueling the continuous growth of the company. Currently, the company’s R&D center boasts a professional and complete team, with more than 30% of the R&D staff holding a master's degree or higher. The team covers a wide range of fields including medicine, biology, mechanical engineering, software, and hardware. The R&D center is composed of four specialized teams: reagent R&D, instrument R&D, clinical, and regulatory, implementing a synchronized development and registration model for both reagents and instruments. This ensures the continuous update of the company's products and breakthroughs in innovative technologies. In 2023, the company was recognized as a Shanghai Municipal Technology R&D Center.
At the time of its establishment, the company created a proprietary technology platform — RNA real-time isothermal amplification detection technology (SAT). On this platform, the company has successively launched a range of innovative pathogen RNA detection products and instruments. The company continues to deeply explore the RNA detection field, constantly innovating and upgrading both technology and products. It has established a multiplex RNA amplification technology platform and a digital RNA absolute quantification technology platform, and is developing new RNA pathogen and tumor detection products on these new platforms.
For over a decade, Rendu Biotech has remained dedicated to the innovative R&D of RNA molecular diagnostic products. The company has launched a series of exclusive products in China, including urine RNA detection products for CT, NG, MG, and UU, exclusive respiratory RNA detection products for Mycoplasma pneumoniae (MP) and Mycobacterium tuberculosis (TB), the world's first HBV RNA (Hepatitis B Virus RNA) and Mycoplasma genitalium RNA (MG RNA). Throughout its deep exploration and continuous innovation in the RNA detection field, Rendu Biotech has undertaken several national key projects, including the National "863" Program, the Science and Technology Support Program, the 12th Five-Year Plan Major Projects, the 13th Five-Year Plan Major Projects/Key R&D Plan, and the 14th Five-Year Plan Key R&D Plan. The company has also been honored multiple times with Shanghai Science and Technology Awards.
Independent innovation is the driving force behind the company. Rendu Biotech is committed to a development path focused on specialization, refinement, and distinctiveness.
Through continuous innovation at the source, the company has established a technological advantage at its core. As of now, Rendu Biotech has 30 registered products and 23 CE-certified products. The company has applied for 94 domestic and international invention patents, including 91 domestic patents and 3 international patents. With its strong innovation capabilities, Rendu Biotech has been recognized as a National Intellectual Property Advantage Enterprise, an MIIT Specialized and Innovative "Little Giant" Enterprise, and a Shanghai High-Tech Enterprise.
Telephone · +86 021-50720200 Address · Building 15B, No. 528 Ruiqing Road, East District, Zhangjiang High tech Park, Shanghai
